Get the Stockscreener App
1.54
5.52%
-0.09
Pre-market:
1.50
-0.04
-2.60%
Calidi Biotherapeutics Inc stock is traded at $1.54, with a volume of 168.39K.
It is down -5.52% in the last 24 hours and up +1,061% over the past month.
Calidi Biotherapeutics Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors. The company was founded in 2014 and is headquartered in San Diego, California.
See More
Previous Close:
$1.63
Open:
$1.57
24h Volume:
168.39K
Relative Volume:
0.04
Market Cap:
$3.77M
Revenue:
-
Net Income/Loss:
$-25.09M
P/E Ratio:
-0.2972
EPS:
-5.1824
Net Cash Flow:
$-18.40M
1W Performance:
-13.97%
1M Performance:
+1,061%
6M Performance:
+96.78%
1Y Performance:
-73.72%
1-Day Range:
$1.50
$1.59
1-Week Range:
$1.50
$1.79
52-Week Range:
$0.095
$6.0594
Calidi Biotherapeutics Inc Stock (CLDI) Company Profile
Name
Calidi Biotherapeutics Inc
Sector
Industry
Phone
(858) 794-9600
Address
4475 Executive Drive, Suite 200, San Diego
Compare CLDI vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLDI
Calidi Biotherapeutics Inc
|
1.54 | 3.99M | 0 | -25.09M | -18.40M | -5.1824 |
VRTX
Vertex Pharmaceuticals Inc
|
516.44 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.97 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
856.94 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
202.00 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
356.01 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Calidi Biotherapeutics Inc Stock (CLDI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-22-23 | Initiated | H.C. Wainwright | Buy |
| Oct-09-23 | Initiated | Robert W. Baird | Outperform |
Calidi Biotherapeutics Inc Stock (CLDI) Latest News
Calidi Biotherapeutics Reports Quarterly Results and Pipeline Progress - TipRanks
Calidi Biotherapeutics Q2 Results: EPS loss widens 48% YoY to $(2.94) - scanx.trade
Calidi Biotherapeutics 2Q 2026: Net loss $4.16M, EPS $(2.94) — 10-Q Summary - TradingView
Form 8K Calidi Biotherapeutics Inc For: 13 August By Investing.com - Investing.com Canada
Calidi Biotherapeutics Reports Positive FDA Pre-IND Feedback for CLD-401, Showcases RedTail Platform Data and Cuts G&A Expenses - Quiver Quantitative
Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights - Yahoo! Finance Canada
Price to book forward of Calidi Biotherapeutics Inc. – OTC:CLDWW - TradingView
Price to sales forward of Calidi Biotherapeutics Inc. – OTC:CLDWW - TradingView
Calidi Biotherapeutics (CLDI) Insider Trading Activity 2026 $CLDI - MarketBeat
Calidi Biotherapeutics Inc (CLDI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Price to sales forward of Calidi Biotherapeutics, Inc. – BOATS:CLDI - TradingView
Calidi Biotherapeutics Inc. (NYSE: CLDI) Share Price, CLDI Stock News, CLDI Share Price & Updates - Kalkine
Calidi Biotherapeutics Announces Reverse Stock Split to Maintain NYSE American Listing – July 2026 8-K Filing - Minichart
Calidi Biotherapeutics Implements Reverse Stock Split on NYSE - TipRanks
Calidi Biotherapeutics Inc (CLDI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CLDI|Calidi Biotherapeutics Inc|Price:0.109|Chg%:+0.009 - TradingKey
Calidi Biotherapeutics Presents New Data on Cytotoxicity - GlobeNewswire
Calidi Biotherapeutics Inc (CLDI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Calidi highlights new EpCam-targeting T-cell engager data - Stock Titan
Calidi Biotherapeutics Inc (CLDI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Calidi Biotherapeutics Inc (CLDI) Cash Flow - TradingKey
Stock Splits Calendar for: - Yahoo! Finance Canada
TradingKey - TradingKey
Calidi Biotherapeutics Inc (CLDI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Calidi Biotherapeutics, Inc. (CLDI) stock price, news, quote and history - Yahoo Finance UK
Calidi Biotherapeutics To Carry Out 1-for-16 Reverse Stock Split On July 31st, 2026 - Moomoo
Calidi Gains on Company Update - Baystreet.ca
Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers - GlobeNewswire
Calidi Cut G&A by About $1M; Targets First Dose in Q1 2027 - Stock Titan
Calidi Biotherapeutics to Effect 1-for-16 Reverse Stock Split - marketscreener.com
Calidi Announces Reverse Stk Split, Expected to Begin Trading on a 1-For-16 Split Adjusted Basis on July 31 - Moomoo
Calidi shareholders will get one share for every 16 held - Stock Titan
Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026 - GlobeNewswire
Calidi Biotherapeutics Plans Relocation Through New Lease Agreements - TipRanks
Calidi Biotherapeutics Signs 44-Month Lease at 5580 Morehouse Drive, San Diego for New Corporate Headquarters - Minichart
New lease could save Calidi Biotherapeutics (NYSE American: CLDI) $1.1M yearly - Stock Titan
Calidi Biotherapeutics (CLDI) Slides Over 8% as Stock Nears Critical Support Level at $0.11Volatility Breakout Picks - dars.gov.et
Calidi Biotherapeutics grants inducement options to new VP Finance - scanx.trade
Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 - The Manila Times
Calidi lures new finance chief with 100,000 stock options - Stock Titan
Calidi Biotherapeutics (CLDI) stock plunges 35% after hours — here's why - MSN
CLDI Q4 2025 Earnings: Surprise EPS Beat Signals Cost Discipline Amid Pre-Revenue PhaseTech Earnings Analysis - dars.gov.et
CLDI Q4 2025 Earnings: Narrower-Than-Expected Loss Fails to Lift SharesRevenue Growth Report - dars.gov.et
Calidi Biotherapeutics (CLDI) director Sanders Corazon files initial Form 3 - Stock Titan
CLDI Q4 2025 Earnings: EPS Surprises with 73.6% Beat as Clinical Pipeline AdvancesAnalyst Consensus Shift - dars.gov.et
CLDI Q4 2025 Earnings: Narrower-than-expected loss boosts shares by 8.88%Low Growth Earnings - dars.gov.et
Calidi Biotherapeutics, Inc. Actuals & Estimates (AMEX:CLDI) - TradingView
Calidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic Summit - Sahm
Calidi’s tumor-targeted T-cell approach aims at hard-to-hit solid tumors - Stock Titan
Calidi Biotherapeutics Presents New Data on CLD-501, Its In - GlobeNewswire
Form 8K Calidi Biotherapeutics Inc For: 23 June By Investing.com - Investing.com Australia
Calidi Biotherapeutics Inc Stock (CLDI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.03%
0.33%
Cap:
|
Volume (24h):